---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040260"
form_type: "8-K"
ticker: "NWBO"
cik: "0001072379"
company_name: "NORTHWEST BIOTHERAPEUTICS INC"
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:58:30.141020+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables

## Summary
- Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
- Payment in installments over 2 years starting 3 months after close, with potential acceleration upon DCVax-L regulatory approval.
- Related-party transaction: CEO Linda Powers controls seller; approved per company policies.
- Company retired 12M shares and cancelled 5.5M stock options previously issued to Advent.
- SEC granted waiver from providing Advent financial statements and pro forma info under Regulation S-X.

## SEC filing metadata
- accession: 0001104659-26-040260
- form_type: 8-K
- ticker: NWBO
- cik: 0001072379
- company_name: NORTHWEST BIOTHERAPEUTICS INC
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/0001104659-26-040260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/tm2611284d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040260
- JSON: https://secwatch.observer/filing/0001104659-26-040260.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040260.txt

## Source-grounded claims
- claim_id: 7228ab7eb3962d6a10943dea73df057025ff00d9
  claim: NORTHWEST BIOTHERAPEUTICS INC completed an acquisition involving Toucan Holdings LLC for purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for (closed 2025-10-24).
  evidence_excerpt: with potential acceleration after regulatory approval of the Company’s DCVax®-L product. The consideration for the acquisition consists of a purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for manufacturing and related services already provided under
  evidence_url: https://www.sec.gov/Archives/edgar/data/1072379/000110465926040260/0001104659-26-040260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.